Crystalline sirolimus-coated balloon (cSCB) angioplasty in an all-comers, patient population with stable and unstable coronary artery disease including chronic total occlusions: rationale, methodology and design of the SCORE trial.

Publikation

Crystalline sirolimus-coated balloon (cSCB) angioplasty in an all-comers, patient population with stable and unstable coronary artery disease including chronic total occlusions: rationale, methodology and design of the SCORE trial.

Wissenschaftlicher Artikel/Review - 31.03.2023

Otto Sylvia, Díaz Victor Alfonso Jiménez, Weilenmann Daniel, Cuculi Florim, Nuruddin Amin Ariff, Leibundgut Gregor, Alfonso Fernando, Wan Ahmad Wan Azman, Pyxaras Stylianos, Rittger Harald, Steen Philip, Gaede Luise, Schulze Christian, Wöhrle Jochen, Rosenberg Mark, Waliszewski Matthias W

Zitation

Otto S, Díaz V, Weilenmann D, Cuculi F, Nuruddin A, Leibundgut G, Alfonso F, Wan Ahmad W, Pyxaras S, Rittger H, Steen P, Gaede L, Schulze C, Wöhrle J, Rosenberg M, Waliszewski M. Crystalline sirolimus-coated balloon (cSCB) angioplasty in an all-comers, patient population with stable and unstable coronary artery disease including chronic total occlusions: rationale, methodology and design of the SCORE trial. BMC Cardiovasc Disord 2023; 23:176.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

BMC Cardiovasc Disord 2023; 23

Veröffentlichungsdatum

31.03.2023

eISSN (Online)

1471-2261

Seiten

176

Kurzbeschreibung/Zielsetzung

A decade ago, the iopromide-paclitaxel coated balloon (iPCB) was added to the cardiologist's toolbox to initially treat in-stent restenosis followed by the treatment of de novo coronary lesions. In the meantime, DES technologies have been substantially improved to address in-stent restenosis and thrombosis, and shortened anti-platelet therapy. Recently, sirolimus-coated balloon catheters (SCB) have emerged to provide an alternative drug to combat restenosis.